1891P Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma

Autor: Saliby, R.M., Jammihal, T., Labaki, C., Soulati, H., Gallegos, J., Peris, A., McCurry, D., Yu, C., Shah, V., Poduval, D., El Zarif, T., El Ahmar, N., Laimon, Y.N., Heng, D.Y.C., Signoretti, S., Van Allen, E.M., Choueiri, T.K., Shukla, S., Braun, D.A.

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S1017-S1017

PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients.

Autor: Denize T; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Jegede OA; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Matar S; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., El Ahmar N; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., West DJ; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Walton E; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Bagheri AS; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Savla V; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Nabil Laimon Y; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Gupta S; Bristol-Myers Squibb, Princeton, New Jersey., Vemula SV; Bristol-Myers Squibb, Princeton, New Jersey., Braun DA; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut., Burke KP; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts., Catalano PJ; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts., Freeman GJ; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Atkins MB; Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC., McDermott DF; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts., Sharpe AH; Harvard Medical School, Boston, Massachusetts.; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts., Choueiri TK; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Signoretti S; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Feb 16; Vol. 30 (4), pp. 803-813.